• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

免疫功能低下的 SARS-CoV-2 奥密克戎变异株感染者在接受 sotrovimab 治疗后出现的耐药性和病毒持续存在情况。

Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant.

机构信息

Department of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands.

Department of Viroscience, Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands.

出版信息

Clin Infect Dis. 2023 Feb 8;76(3):e507-e509. doi: 10.1093/cid/ciac601.

DOI:10.1093/cid/ciac601
PMID:35867699
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9384506/
Abstract

Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated with sotrovimab resistance were documented in 6; viral replication continued after 30 days in 5. Combination antibody therapy may be required to avoid acquired resistance in immunocompromised patients.

摘要

对 47 名接受索特罗维单抗治疗的免疫功能低下患者的病毒进化情况进行了评估。16 例患者的治疗后 SARS-CoV-2 测序成功。6 例患者中记录了与索特罗维单抗耐药相关的突变；5 例患者在 30 天后病毒仍持续复制。免疫功能低下患者可能需要联合抗体治疗以避免获得性耐药。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0815/9907529/f04be9d13280/ciac601f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0815/9907529/f04be9d13280/ciac601f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0815/9907529/f04be9d13280/ciac601f1.jpg

相似文献

1
Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant.免疫功能低下的 SARS-CoV-2 奥密克戎变异株感染者在接受 sotrovimab 治疗后出现的耐药性和病毒持续存在情况。
Clin Infect Dis. 2023 Feb 8;76(3):e507-e509. doi: 10.1093/cid/ciac601.
2
Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients.严重急性呼吸综合征冠状病毒 2 型奥密克戎感染免疫功能低下患者中索托维单抗逃逸变异的快速选择。
Clin Infect Dis. 2023 Feb 8;76(3):408-415. doi: 10.1093/cid/ciac802.
3
Emergence of Delta and Omicron variants carrying resistance-associated mutations in immunocompromised patients undergoing sotrovimab treatment with long-term viral excretion.携带耐药相关突变的德尔塔和奥密克戎变异株在接受索特罗维单抗治疗并长期病毒排出的免疫功能低下患者中出现。
Clin Microbiol Infect. 2023 Feb;29(2):240-246. doi: 10.1016/j.cmi.2022.08.021. Epub 2022 Sep 5.
4
Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study.索特罗维单抗治疗 SARS-CoV-2 奥密克戎变异株感染住院患者：一项倾向性评分匹配回顾性队列研究。
Microbiol Spectr. 2023 Feb 14;11(1):e0410322. doi: 10.1128/spectrum.04103-22. Epub 2022 Dec 8.
5
Favorable Outcome Following Sotrovimab Monoclonal Antibody in a Patient with Prolonged SARS-CoV-2 Omicron Infection with HIV/AIDS.Sotrovimab 单克隆抗体治疗 HIV/AIDS 合并长期 SARS-CoV-2 奥密克戎感染患者取得良好转归。
Intern Med. 2022 Nov 15;61(22):3459-3462. doi: 10.2169/internalmedicine.0485-22. Epub 2022 Sep 6.
6
Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2.免疫功能低下的 SARS-CoV-2 感染者对抗病毒和抗体治疗的耐药性突变。
Med. 2023 Nov 10;4(11):813-824.e4. doi: 10.1016/j.medj.2023.08.001. Epub 2023 Sep 7.
7
Clinical Characteristics and Outcomes of Immunocompromised Patients With Coronavirus Disease 2019 Caused by the Omicron Variant: A Prospective, Observational Study.奥密克戎变异株所致 2019 冠状病毒病免疫功能低下患者的临床特征和结局：一项前瞻性、观察性研究。
Clin Infect Dis. 2023 Feb 8;76(3):e172-e178. doi: 10.1093/cid/ciac571.
8
SARS-CoV-2 evolution during prolonged infection in immunocompromised patients.免疫功能低下患者体内 SARS-CoV-2 的长时间感染过程中的进化。
mBio. 2024 Mar 13;15(3):e0011024. doi: 10.1128/mbio.00110-24. Epub 2024 Feb 16.
9
Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab.在接受索特罗维单抗治疗的 SARS-CoV-2 患者中，复杂的宿主内基因组动态后频繁出现耐药突变。
Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0026623. doi: 10.1128/aac.00266-23. Epub 2023 Jun 6.
10
Experience with sotrovimab treatment of SARS-CoV-2-infected patients in Denmark.丹麦感染 SARS-CoV-2 患者使用 sotrovimab 治疗的经验。
Br J Clin Pharmacol. 2023 Jun;89(6):1820-1833. doi: 10.1111/bcp.15644. Epub 2023 Jan 13.

引用本文的文献

1
COVID-19 in immunocompromised patients: proposed definition of a new entity with prolonged infection.免疫功能低下患者的新冠病毒病：关于一种新的持续性感染实体的拟议定义
New Microbes New Infect. 2025 Aug 21;67:101626. doi: 10.1016/j.nmni.2025.101626. eCollection 2025 Oct.
2
Clinical and molecular landscape of prolonged SARS-CoV-2 infection with resistance to remdesivir in immunocompromised patients.免疫功能低下患者中对瑞德西韦耐药的新型冠状病毒2（SARS-CoV-2）持续感染的临床和分子特征
PNAS Nexus. 2025 Mar 18;4(4):pgaf085. doi: 10.1093/pnasnexus/pgaf085. eCollection 2025 Apr.
3
A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation.

本文引用的文献

1
Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial.特免球蛋白治疗 2019 冠状病毒病住院严重免疫功能低下患者：一项随机对照试验。
J Infect Dis. 2023 Jan 11;227(2):206-210. doi: 10.1093/infdis/jiac334.
2
Drivers of adaptive evolution during chronic SARS-CoV-2 infections.慢性 SARS-CoV-2 感染期间适应性进化的驱动因素。
Nat Med. 2022 Jul;28(7):1501-1508. doi: 10.1038/s41591-022-01882-4. Epub 2022 Jun 20.
3
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies.
一种中和含L452R突变的新冠病毒奥密克戎变种的人源单克隆抗体。
J Virol. 2024 Dec 17;98(12):e0122324. doi: 10.1128/jvi.01223-24. Epub 2024 Nov 4.
4
Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections.免疫功能低下且持续性感染患者体内具有抗药性的 SARS-CoV-2 变种的出现，降低了对这些抗病毒药物的敏感性。
Nat Commun. 2024 Sep 18;15(1):7999. doi: 10.1038/s41467-024-51924-3.
5
Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections.在患有持续性感染的免疫功能低下患者中，出现了对抗病毒药物敏感性降低的可传播的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体。
medRxiv. 2024 Jun 18:2024.06.14.24308523. doi: 10.1101/2024.06.14.24308523.
6
Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2.针对严重急性呼吸综合征冠状病毒 2 的单克隆抗体与双抗单抗治疗抵抗和病毒动力学的特征。
J Infect Dis. 2024 Aug 16;230(2):394-402. doi: 10.1093/infdis/jiae192.
7
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs.SARS-CoV-2 对单克隆抗体和小分子药物的耐药性。
Cell Chem Biol. 2024 Apr 18;31(4):632-657. doi: 10.1016/j.chembiol.2024.03.008.
8
Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.245例免疫功能低下患者中针对新冠病毒变异株的单克隆抗体疗法的临床和病毒学结果：一项多中心前瞻性队列研究
Clin Infect Dis. 2024 Jun 14;78(6):1514-1521. doi: 10.1093/cid/ciae026.
9
A Short Update on the Use of Monoclonal Antibodies in COVID-19.关于 COVID-19 中使用单克隆抗体的最新进展。
AAPS J. 2024 Mar 5;26(2):30. doi: 10.1208/s12248-024-00904-y.
10
Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants.索特罗维单抗：对 SARS-CoV-2 变异株疗效的评价。
Viruses. 2024 Jan 31;16(2):217. doi: 10.3390/v16020217.
严重急性呼吸综合征冠状病毒2型奥密克戎亚变体对治疗性单克隆抗体的中和敏感性
Lancet Infect Dis. 2022 Jul;22(7):942-943. doi: 10.1016/S1473-3099(22)00365-6. Epub 2022 Jun 9.
4
Early Outpatient Treatment for Covid-19 with Convalescent Plasma.Covid-19 的早期门诊康復期血浆治疗。
N Engl J Med. 2022 May 5;386(18):1700-1711. doi: 10.1056/NEJMoa2119657. Epub 2022 Mar 30.
5
Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use.使用索托维单抗后新冠病毒德尔塔变异株中的耐药突变
N Engl J Med. 2022 Apr 14;386(15):1477-1479. doi: 10.1056/NEJMc2120219. Epub 2022 Mar 9.
6
Antibody evasion properties of SARS-CoV-2 Omicron sublineages.SARS-CoV-2 奥密克戎亚谱系的抗体逃逸特性。
Nature. 2022 Apr;604(7906):553-556. doi: 10.1038/s41586-022-04594-4. Epub 2022 Mar 3.
7
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients.免疫功能低下的成人血液病患者中 mRNA-1273 COVID-19 疫苗接种反应的定量分析。
Blood Adv. 2022 Mar 8;6(5):1537-1546. doi: 10.1182/bloodadvances.2021006917.
8
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.一种传染性 SARS-CoV-2 B.1.1.529 奥密克戎病毒能够逃避治疗性单克隆抗体的中和作用。
Nat Med. 2022 Mar;28(3):490-495. doi: 10.1038/s41591-021-01678-y. Epub 2022 Jan 19.
9
The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant.RECOVAC 免疫反应研究：COVID-19 疫苗在慢性肾脏病、透析或肾移植患者中的免疫原性、耐受性和安全性。
Transplantation. 2022 Apr 1;106(4):821-834. doi: 10.1097/TP.0000000000003983.
10
SARS-CoV-2 Variants in Patients with Immunosuppression.免疫抑制患者中的新型冠状病毒2型变体
N Engl J Med. 2021 Aug 5;385(6):562-566. doi: 10.1056/NEJMsb2104756.